1 enrolling by invitation. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Enrolling by invitation 1 |
Follow Lucentis: new trials by email Literature Review of Lucentis trials Research Report on Lucentis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMD Standard of Care, Ranibizumab - Neovascular Age-Related Macular Degeneration (nAMD) | Phase 2 | Enrolling by invitation | AbbVie | 116 | 2021-12-20 | 2026-08-05 |
AbbVie (1)
United States (1)